Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Until today this year the stock’s price performance recorded an increase of 36.31%. However, over the last six months, the performance has been weaker by 43.30%. The price of MLYS increased 81.41% over the last 30 days. And in the last five days, it has surged by 8.75%.
Mineralys Therapeutics Inc’s stock has seen a smooth market performance. The company’s stock achieved a 1-year high of $18.38 on 03/19/25, and the lowest price during that time was $8.24, recorded on 02/25/25.
52-week price history of MLYS Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Mineralys Therapeutics Inc’s current trading price is -8.71% away from its 52-week high, while its distance from the 52-week low is 103.62%. The stock’s price range for this period has been between $8.24 and $18.38. The Healthcare sector company’s shares saw a trading volume of about 1.34 million for the day, which was higher than the average daily volume of 0.82 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Mineralys Therapeutics Inc (MLYS) has experienced a quarterly rise of 41.84% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.05B and boasts a workforce of 51 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 11.93, with a change in price of +2.89. Similarly, Mineralys Therapeutics Inc recorded 585,307 in trading volume during the last 100 days, posting a change of +20.81%.
MLYS’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for MLYS stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
MLYS Stock Stochastic Average
As of today, the raw stochastic average of Mineralys Therapeutics Inc over the past 50 days is 84.22%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 83.50%. Additionally, the Stochastic %K and %D values for the company were 82.27% and 82.96%, respectively, over the past 20 days.
